Charles River Laboratories International, Inc. (CRL)
-NYSE 44.39 
0.04(0.09%) May 24, 4:02PM EDT
| Prev Close: | 44.35 |
|---|
| Open: | 44.17 |
|---|
| Bid: | 40.41 x 100 |
|---|
| Ask: | 46.00 x 200 |
|---|
| 1y Target Est: | 43.44 |
|---|
| Beta: | 1.2 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 43.68 - 44.54 |
|---|
| 52wk Range: | 31.48 - 46.90 |
|---|
| Volume: | 166,563 |
|---|
| Avg Vol (3m): | 560,756 |
|---|
| Market Cap: | 2.18B |
|---|
| P/E (ttm): | 22.23 |
|---|
| EPS (ttm): | 2.00 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CHARLES RIVER LABORATORIES INTERNATIONAL INC FinancialsEDGAR Online Financials(Wed, May 15)
- Cramer's Mad Money - 3 Things Driving The Market Higher (5/13/13)at Seeking Alpha(Tue, May 14)
- [video] What's Working in Pharmaat CNBC(Mon, May 13)
- The Danger of Chasing This IPO's Profitsat Motley Fool(Mon, May 13)
- CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 10)
- Pharmaceutical services provider Quintiles surges on first day of tradingat theflyonthewall.com(Thu, May 9)
- CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Charles River Laboratories to Present at Baird’s Growth Stock ConferenceBusiness Wire(Mon, May 6)
- 3 Healthcare Stock Winners and 1 Loser Post Earningsat Wall St. Cheat Sheet(Sat, May 4)
- [video] No Huddle Offense: What's Working In Pharmaat CNBC(Fri, May 3)
- Cramer's Mad Money - The Most Important Game Changer For 2013 (5/2/13)at Seeking Alpha(Fri, May 3)
- Cramer's Top Stock Picks: AGN BP CRL PRU AIGat TheStreet(Fri, May 3)
- Cramer's 'Mad Money' Recap: A New Dawn for Europe?at TheStreet(Thu, May 2)
- Charles River Laboratories International Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
- [video] Charles River CEO: Had a Negligible Impact From Sequesterat CNBC(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | 14.55 |
|---|
| P/S (ttm): | 1.92 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.82 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.72 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | 2.01 |
|---|
Business Summary
Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process.
View More